Chiang KP, Gerber AL, Sipe JC, Cravatt BF2004. Reduced cellular expression and activity of the P129T mutant of human fatty acid amide hydrolase: evidence for a link between defects in the endocannabinoid system and problem drug use. Hum Mol Genet13:2113—19.
2.
Flanagan JM, Gerber AL, Cadet JL, Beutler E., Sipe JC2006. The fatty acid amide hydrolase 385 A/A (P129T) variant: haplotype analysis of an ancient missense mutation and validation of risk for drug addiction. Hum Genet120:581—88.
3.
Hansson AC, Bermudez-Silva FJ, Malinen H., Hyytia P., Sanchez-Vera I., Rimondini R., Rodrigues de Fonseca F., Kunos G., Sommer WH, Heilig M.2007. Genetic impairment of frontocortical endocannabinoid degradation and high alcohol preference. Neuropsychopharmacology32:117—26.
4.
Brisbare-Roch C., Dingemanse J., Koberstein R., Hoever P., Aissaoui H., Flores S., Mueller C., Nayler O., van Gerven J., de Haas SL, Hess P., Qiu C., Buchmann S., Scherz M., Weller T., Fischli W., Clozel M., Jenck F.2007. Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat Med13:150—5.
5.
Dauvilliers Y., Arnulf I., Mignot E.2007. Narcolepsy with cataplexy. Lancet369:499—511.
6.
Barzilai N., Atzmon G., Derby CA, Bauman JM, Lipton RB2006. A genotype of exceptional longevity is associated with preservation of cognitive function. Neurology67:2170—5.
